Jiang B, Zhu Z Z, Liu F, Yang L J, Zhang W Y, Yuan H H, Wang J G, Hu X H, Huang G
Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China.
Genet Mol Res. 2011 Aug 26;10(3):1856-65. doi: 10.4238/vol10-3gmr1071.
Signal transducer and activator of transcription protein 3 (STAT3) has been implicated in cancer development and is recognized as a type of oncogene. However, association studies of single nucleotide polymorphisms (SNPs) in the STAT3 gene with cancer risk are rare and not available for lung cancer. We examined whether STAT3 polymorphisms are associated with the risk of non-small cell lung cancer (NSCLC). Eight SNPs in the STAT3 gene were genotyped by TaqMan assays in 326 NSCLC cases and 432 controls in a Chinese population. Significant decreased risk of NSCLC was observed for carriers of minor alleles rs4796793 (odds ratio (OR) = 0.68, 95% confidence interval (CI) = 0.51-0.92), rs7211777 (OR = 0.67, 95%CI = 0.50-0.90), rs12949918 (OR = 0.73, 95%CI = 0.54-0.97), rs744166 (OR = 0.69, 95%CI = 0.51-0.92), rs9912773 (OR = 0.75, 95%CI = 0.55-0.98), and rs3869550 (OR = 0.70, 95%CI = 0.53-0.94). The GGCGGC haplotype, comprised of minor alleles of the six NSCLC-associated SNPs, had a 0.78-fold (95%CI = 0.62-0.97) significantly decreased risk of NSCLC, as compared to the most common haplotype of CATACT. Stratification analyses by clinical stage showed that the trend for the association between STAT3 polymorphisms and NSCLC risk was present both for stage I/II and stage III/IV, and appeared moderately stronger for stage III/IV. We conclude that polymorphisms in the STAT3 gene may have a protective role in the development of NSCLC, particular of stage III/IV NSCLC.
信号转导与转录激活蛋白3（STAT3）与癌症发展有关，被认为是一种癌基因。然而，关于STAT3基因单核苷酸多态性（SNP）与癌症风险的关联研究很少，且尚无针对肺癌的此类研究。我们研究了STAT3基因多态性是否与非小细胞肺癌（NSCLC）风险相关。在中国人群的326例NSCLC病例和432例对照中，通过TaqMan分析对STAT3基因中的8个SNP进行了基因分型。对于次要等位基因rs4796793（比值比（OR）=0.68，95%置信区间（CI）=0.51-0.92）、rs7211777（OR = 0.67，95%CI = 0.50-0.90）、rs12949918（OR = 0.73，95%CI = 0.54-0.97）、rs744166（OR = 0.69，95%CI = 0.51-0.92）、rs9912773（OR = 0.75，95%CI = 0.55-0.98）和rs3869,550（OR = 0.70，95%CI = 0.53-0.94）的携带者，观察到NSCLC风险显著降低。与最常见的CATACT单倍型相比，由六个与NSCLC相关的SNP的次要等位基因组成的GGCGGC单倍型，NSCLC风险显著降低0.78倍（95%CI = 0.62-0.97）。按临床分期进行分层分析表明，STAT3基因多态性与NSCLC风险之间的关联趋势在I/II期和III/IV期均存在，且在III/IV期似乎稍强。我们得出结论，STAT3基因多态性可能对NSCLC的发生发展具有保护作用，尤其是对III/IV期NSCLC。
